
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY ® Vitreoretinal Cataract System (VCS) and UNITY ® Cataract System (CS). The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to deliver superior efficiency for vitreoretinal and cataract surgery, while enabling exceptional outcomes for patients. 2,4-6,* The systems feature many first-to-market technologies designed to deliver transformative surgical innovation for cataract and vitreoretinal surgery, including UNITY 4D Phaco, HYPERVIT ® 30K and the advanced UNITY Intelligent Fluidics system. 1,4-7 With UNITY VCS/CS, surgeons can operate at more physiologic conditions without compromising efficiency. 1 Surgeons will have the opportunity for hands on experience with UNITY VCS/CS during the 2025 American Society for Cataract and Refractive Surgeons annual meeting (ASCRS, Los Angeles, April 25-28) at the Alcon Booth (#1815).
'Alcon has a long legacy of advancing phaco and vitreoretinal technology for surgical ophthalmology. With UNITY VCS/CS, we are introducing more than a dozen innovations designed to transform surgical outcomes while delivering significant efficiencies for surgery centers across the globe,' said David Endicott, CEO of Alcon. 'This tremendous accomplishment could not have been achieved without those who participated in the development process, including the surgeons who have been evaluating the machines in their practices over the last year. We are excited to start shipping inventory next month so more practices can experience this extraordinary innovation.'
The combination vitreoretinal and cataract system intelligently transforms vitreoretinal and cataract surgery with significant innovation. With the introduction of UNITY Intelligent Fluidics, a unique pressure and flow control technology with real-time sensing, surgeons can expect surgical stability and efficiency at each step of the procedure. 1 Significant advancements in instrumentation for vitreoretinal surgery include:
UNITY 27 Gauge Portfolio: Instrumentation that through breakthrough design and the inclusion of the Dynamic Stiffener technology, surpasses the limitations of traditional 27-gauge tools, delivering the stiffness of a 25-gauge system or better, in a smaller gauge. 6
UNITY TetraSpot: A multi-spot illuminated laser probe that reduces laser application time by up to three times, enabling surgeons to deliver one, two, or four simultaneous laser spots for greater procedural versatility. 5,‡
UNITY Illumination: Reduces blue light exposure to the eye and includes customizable light profiles for excellent tissue visualization, while providing up to 10,000 hours of reliability. 1,8
'UNITY VCS has truly revolutionized the way I can perform during vitreoretinal surgeries,' said Maria H. Berrocal, MD, CEO, Drs. Berrocal & Associates. 'During my approximately 130 cases with this new technology, I saw efficiencies across surgery types. The unique fluidics control together with the faster cutting speeds have certainly been a game-changer, as well as the 27 gauge portfolio—taking the instrumentation to the next level with stiffness and performance similar to 25 gauge—all delivering stability and efficiency throughout the procedure.'
The UNITY VCS/CS system is designed to allow cataract surgeons to operate with increased stability and efficiency at more physiologic conditions through its Intelligent Fluidics functionality. 1 This new technology maintains a consistent level of intraocular pressure (IOP) ∞ to help support patient comfort during surgery, while allowing for higher average vacuum during lens removal. 1 Other surgical performance enhancements include:
UNITY Intelligent Sentry: Maintains anterior chamber stability while improving upon CENTURION ® Vision System with ACTIVE SENTRY ®, reducing post-occlusion surge volumes by 44%. 9,*
UNITY Thermal Sentry: The first phacoemulsification handpiece that features a thermal sensor that works with a proprietary algorithm to estimate incision temperature in real-time and regulate ultrasound power. 1
'I perform thousands of cataract surgeries each year and UNITY VCS/CS has streamlined my surgical procedures while enabling us to consistently deliver exceptional patient outcomes,' said John Berdahl, MD. 'The UNITY 4D phaco technology in particular has been impressive—breaking up even large, dense cataracts efficiently, while maintaining more physiologic IOP throughout the surgery. Beyond the device performance, it expedites our surgical workflow and introduces significant usability improvements—which the entire team greatly appreciates.'
UNITY VCS/CS is the first product to become available from Alcon's UNITY portfolio of next-generation surgical equipment solutions. UNITY VCS/CS users can benefit from Intelligent Services Solutions, including select remote service offerings and predictive service capabilities to minimize downtime. UNITY VCS has received CE Mark, and regulatory approvals in Australia, Japan and the U.S. Inventory will begin shipping to Australia, Europe, Japan and the U.S. from May onwards; and to other markets in third quarter of 2025 pending regulatory approvals. Surgeons attending the ASCRS annual meeting can demo the UNITY VCS/CS platform at Alcon Booth #1815. For more information, please visit MyAlcon.com or speak to your Alcon Sales Representative.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
About UNITY ® VCS/CS
Indications / Intended Use: The UNITY ® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY ® CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.
* Based on bench data; reduction in surge is correlated to less change in anterior chamber depth.
† Based on N=10 handpieces, Artificial cataract lens IOP 55mmhg vacuum of 450 mmHg.
‡ Multiple-spot laser probe (4) is 3 times faster than single-spot laser probe.
∞ Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively.
References
UNITY™ VCS and CS User Manual.
Alcon Data on File, 2024. [REF-24644]
Irannejad A, Tambat S, Abulon DJK. Retropulsion and Mass flow of 27-gauge Vitrectomy Probes: Comparison of Dual-blade/flat-tipped probes and single-blade/beveled probes. 2021. Poster presentation.
Alcon Data on File, 2024. [REF-24379]
Alcon Data on File, 2024. [REF-24615]
Alcon Data on File, 2024. [REF-24576]
Unity Phaco Handpiece Directions for Use.
Alcon Data on File, 2024. [REF-24760]
Alcon Data on File, 2024. [REF-25562]
Connect with us on
Facebook
LinkedIn
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
27 minutes ago
- Business Wire
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company's dividend payout, from $0.28 to $0.02 and would 'redirect those funds to debt reduction.' On this news, Organon's stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Organon's optimistic reports of the dividend payout as the Company's 'number one priority,' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; (2) Organon planned to prioritize debt reduction following the Company's acquisition of Dermavant; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Organon securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
30 minutes ago
- Yahoo
La Jolla Cosmetic Medical Spa Opens Third Location in Temecula on June 2nd
San Diego's Most Trusted Med Spa Expands to the Inland Empire with Award-Winning Aesthetic Services TEMECULA, Calif., June 5, 2025 /PRNewswire/ -- La Jolla Cosmetic Medical Spa (LJC), a leader in aesthetic care for over three decades, is proud to announce the opening of its third medical spa location in Temecula, California, which opened on Monday, June 2, 2025. This new location brings LJC's award-winning services to the heart of the Temecula Valley. Founded in 1988, the La Jolla Cosmetic brand has been a staple of San Diego's aesthetic community for 35+ years. With medical spa locations in La Jolla and Carlsbad, the practice has earned recognition as an 8-time winner of "Best of San Diego" and is currently named a Top 10 Allergan provider in the nation for injectables like BOTOX® and JUVÉDERM®. Now expanding into Riverside County, LJC continues its mission to make world-class aesthetic care more accessible across Southern California. "Opening in Temecula marks a major milestone in our mission to provide personalized, natural results and build long-term relationships with our patients across Southern California," said Lauren Amico Reed, PA-C, MMS, Co-founder of La Jolla Cosmetic Medical Spa. "We are thrilled to bring our team's expertise and renowned aesthetic care to this incredible community." The Temecula location will offer the full range of LJC's most popular non-surgical services, including: Injectables: BOTOX®, JUVÉDERM®, Sculptra®, and more Skin Rejuvenation: HALO® laser, BBL Hero®, threads, microneedling, and medical-grade facials Hair & Wellness Treatments: Regenerative treatments for hair thinning and sexual wellness injectables Patients can expect the same elevated experience that has made LJC a trusted name in aesthetics—from highly trained providers to personalized treatment plans, all in a welcoming, luxurious setting. With this new location, the brand strengthens its vision of blending clinical excellence with deep community connection. Appointments for the Temecula location can be booked at or by calling (858) 228-4542. To celebrate the launch, LJC is offering an exclusive pre-sale special: 40 units of BOTOX® for $299 for a limited time. Additionally, the official grand opening celebration will be held on Saturday, July 19, from 12 p.m. to 3 p.m. Guests can enjoy: Exciting giveaways Exclusive swag bags for the first arrivals Live treatment demos Light bites and refreshments Fun activities and a chance to tour the new space RSVP: La Jolla Cosmetic Medical Spa – Temecula Grand Opening Event! About La Jolla Cosmetic Medical SpaLa Jolla Cosmetic Medical Spa (LJC) has been helping patients look and feel their best since 2013. Known for delivering natural-looking results through expert providers, advanced technology, and personalized care, LJC sets the standard for aesthetic excellence. With medical spa locations in La Jolla, Carlsbad, and now Temecula, LJC continues to set the standard for aesthetic care in Southern California. View original content to download multimedia: SOURCE La Jolla Cosmetic Medical Spa Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
38 minutes ago
- Business Wire
Deadline Alert: Red Cat Holdings, Inc. (RCAT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. ('Red Cat' or the 'Company') (NASDAQ: RCAT) securities between , inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR RED CAT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? In March 2022, Red Cat announced that its subsidiary Teal Drones, Inc. ('Teal') had been selected to compete in Tranche 2 of the U.S. Army's Short Range Reconnaissance Program of Record (the 'SRR Program'). On July 27, 2023, Red Cat released its fiscal year 2023 financial results and revealed that its Salt Lake City Facility could only produce 100 drones per month and that construction of the facility was only 'substantially completed' and, while it could potentially reach a production capacity of one thousand drones per month over the next two to three years, it would require additional capital investments. On this news, Red Cat's stock price fell $0.10, or 8.9%, to close at $1.02 per share on July 28, 2023, thereby injuring investors. Then, on September 23, 2024, Red Cat released its first quarter fiscal 2025 financial results, missing consensus estimates and disclosing that it had spent 'the past four months . . . retooling [the Salt Lake City Facility] and preparing for high volume production[,]' while admitting that a 'pause in manufacturing of Teal 2 and building our Army prototypes impacted Teal 2 sales' because it 'couldn't produce and sell Teal 2 units while retooling [its] factory.' On this news, Red Cat's stock price fell $0.80, or 25.3%, over two consecutive trading days to close at $2.36 per share on September 25, 2024. Then, on November 19, 2024, Red Cat announced that it had won the SRR contract, stating that it was worth potentially hundreds of millions of dollars. However, on January 16, 2025, Kerrisdale Capital published a report alleging, among other things, that Red Cat had overstated that value of the SRR Contract and that it was worth approximately $20-25 million, based on U.S. Army budget documents. On this news, Red Cat's stock price fell $2.35, or 21.5%, over two consecutive trading days to close at $8.56 per share on January 17, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Red Cat securities during the Class Period, you may move the Court no later than July 22, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.